199 related articles for article (PubMed ID: 36769158)
61. Target actionability review to evaluate CDK4/6 as a therapeutic target in paediatric solid and brain tumours.
Schubert NA; Chen CY; Rodríguez A; Koster J; Dowless M; Pfister SM; Shields DJ; Stancato LF; Vassal G; Caron HN; van den Boogaard ML; Henssen AG; Molenaar JJ
Eur J Cancer; 2022 Jul; 170():196-208. PubMed ID: 35671543
[TBL] [Abstract][Full Text] [Related]
62. Cytoplasmic cyclin D1 regulates glioblastoma dissemination.
Cemeli T; Guasch-Vallés M; Nàger M; Felip I; Cambray S; Santacana M; Gatius S; Pedraza N; Dolcet X; Ferrezuelo F; Schuhmacher AJ; Herreros J; Garí E
J Pathol; 2019 Aug; 248(4):501-513. PubMed ID: 30957234
[TBL] [Abstract][Full Text] [Related]
63. Tissue plasminogen activator expression in meningiomas and glioblastomas.
Goh KY; Poon WS; Chan DT; Ip CP
Clin Neurol Neurosurg; 2005 Jun; 107(4):296-300. PubMed ID: 15885387
[TBL] [Abstract][Full Text] [Related]
64. MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone.
Dujardin F; Binh MB; Bouvier C; Gomez-Brouchet A; Larousserie F; Muret Ad; Louis-Brennetot C; Aurias A; Coindre JM; Guillou L; Pedeutour F; Duval H; Collin C; de Pinieux G
Mod Pathol; 2011 May; 24(5):624-37. PubMed ID: 21336260
[TBL] [Abstract][Full Text] [Related]
65. Analysis of dysregulated long non-coding RNA expressions in glioblastoma cells.
Balci T; Yilmaz Susluer S; Kayabasi C; Ozmen Yelken B; Biray Avci C; Gunduz C
Gene; 2016 Sep; 590(1):120-2. PubMed ID: 27306825
[TBL] [Abstract][Full Text] [Related]
66. Strategic Development of an Immunotoxin for the Treatment of Glioblastoma and Other Tumours Expressing the Calcitonin Receptor.
Gupta P; Hare DL; Wookey PJ
Cells; 2021 Sep; 10(9):. PubMed ID: 34571996
[TBL] [Abstract][Full Text] [Related]
67. Worse outcome in primary glioblastoma multiforme with concurrent epidermal growth factor receptor and p53 alteration.
Ruano Y; Ribalta T; de Lope AR; Campos-Martín Y; Fiaño C; Pérez-Magán E; Hernández-Moneo JL; Mollejo M; Meléndez B
Am J Clin Pathol; 2009 Feb; 131(2):257-63. PubMed ID: 19141386
[TBL] [Abstract][Full Text] [Related]
68. SAMSN1 is highly expressed and associated with a poor survival in glioblastoma multiforme.
Yan Y; Zhang L; Xu T; Zhou J; Qin R; Chen C; Zou Y; Fu D; Hu G; Chen J; Lu Y
PLoS One; 2013; 8(11):e81905. PubMed ID: 24278465
[TBL] [Abstract][Full Text] [Related]
69. An integrated transcriptomic and computational analysis for biomarker identification in human glioma.
Xing W; Zeng C
Tumour Biol; 2016 Jun; 37(6):7185-92. PubMed ID: 26663173
[TBL] [Abstract][Full Text] [Related]
70. The emergent role of exosomes in glioma.
Gourlay J; Morokoff AP; Luwor RB; Zhu HJ; Kaye AH; Stylli SS
J Clin Neurosci; 2017 Jan; 35():13-23. PubMed ID: 27771233
[TBL] [Abstract][Full Text] [Related]
71. CDK4 overexpression is a predictive biomarker for resistance to conventional chemotherapy in patients with osteosarcoma.
Iwata S; Tatsumi Y; Yonemoto T; Araki A; Itami M; Kamoda H; Tsukanishi T; Hagiwara Y; Kinoshita H; Ishii T; Nagase H; Ohira M
Oncol Rep; 2021 Jul; 46(1):. PubMed ID: 34036394
[TBL] [Abstract][Full Text] [Related]
72. Elevated expression of CDK4 in lung cancer.
Wu A; Wu B; Guo J; Luo W; Wu D; Yang H; Zhen Y; Yu X; Wang H; Zhou Y; Liu Z; Fang W; Yang Z
J Transl Med; 2011 Apr; 9():38. PubMed ID: 21477379
[TBL] [Abstract][Full Text] [Related]
73. The cyclin D1-CDK4 oncogenic interactome enables identification of potential novel oncogenes and clinical prognosis.
Jirawatnotai S; Sharma S; Michowski W; Suktitipat B; Geng Y; Quackenbush J; Elias JE; Gygi SP; Wang YE; Sicinski P
Cell Cycle; 2014; 13(18):2889-900. PubMed ID: 25486477
[TBL] [Abstract][Full Text] [Related]
74. Basic Gene Expression Characteristics of Glioma Stem Cells and Human Glioblastoma.
Sakamoto D; Takagi T; Fujita M; Omura S; Yoshida Y; Iida T; Yoshimura S
Anticancer Res; 2019 Feb; 39(2):597-607. PubMed ID: 30711935
[TBL] [Abstract][Full Text] [Related]
75. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas.
Watanabe K; Tachibana O; Sata K; Yonekawa Y; Kleihues P; Ohgaki H
Brain Pathol; 1996 Jul; 6(3):217-23; discussion 23-4. PubMed ID: 8864278
[TBL] [Abstract][Full Text] [Related]
76. Centromere protein J is overexpressed in human glioblastoma and promotes cell proliferation and migration.
de Freitas GPA; Geraldo LHM; Faria BM; Alves-Leon SV; de Souza JM; Moura-Neto V; Pontes B; Romão LF; Garcez PP
J Neurochem; 2022 Sep; 162(6):501-513. PubMed ID: 35797221
[TBL] [Abstract][Full Text] [Related]
77. The role of extracellular-5'-nucleotidase/CD73 in glioma peritumoural brain edema.
Wang B; Wang D; Zhu Z; Wang W; Zhang X; Tang F; Zhou Y; Wang H; Liu M; Yao X; Yan X
Neurol Sci; 2016 Apr; 37(4):603-11. PubMed ID: 26884147
[TBL] [Abstract][Full Text] [Related]
78. NAP1L1 promotes proliferation and chemoresistance in glioma by inducing CCND1/CDK4/CDK6 expression through its interaction with HDGF and activation of c-Jun.
Chen Z; Xie Y; Luo H; Song Y; Que T; Hu R; Huang H; Luo K; Li C; Qin C; Zheng C; Fang W; Liu L; Long H; Luo Q
Aging (Albany NY); 2021 Dec; 13(24):26180-26200. PubMed ID: 34959221
[TBL] [Abstract][Full Text] [Related]
79. Quantitative histology of peritumoural low density area associated with glioma on CT; image analyzing study of peritumoural low density area after steroid-osmotherapy.
Yoshii Y; Tosa J; Maki Y; Narushima A; Matsuki T
Acta Neurochir (Wien); 1986; 81(1-2):61-7. PubMed ID: 3728092
[TBL] [Abstract][Full Text] [Related]
80. Over-expression of BMPR-IB reduces the malignancy of glioblastoma cells by upregulation of p21 and p27Kip1.
Liu S; Yin F; Fan W; Wang S; Guo XR; Zhang JN; Tian ZM; Fan M
J Exp Clin Cancer Res; 2012 May; 31(1):52. PubMed ID: 22650359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
